GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. 

On Thursday, the partners announced that Surface Oncology Inc. (NASDAQ:SURF) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive worldwide development and commercial rights to SRF813, a fully human IgG1 antibody targeting NK cell checkpoint PVRIG in preclinical development. ...